Hematological Malignancy Clinical Trial
Official title:
Prospective Clinical Evaluation of Bata-D-Glucan Assay for Diagnosis of Invasive Fungal Infection in Blood and Bronchoalveolar Lavage
In patients with invasive fungal infection (IFI) rapid diagnosis is essential for early initiation of appropriate antifungal therapy and thereby survival. Conventional culture is still the Gold-Standard for diagnosis of IFI. Sensitivity of conventional culture, however, is low (50%) and time to results minimum 24 hours. Therefore usage of serological tests detecting fungal antigens has increased dramatically over recent years. Main advantages of this new methods are rapid results and higher sensitivity when compared to conventional culture. One of the most promising serological marker currently used is beta-D-Glucan, which is a component of the fungal cell wall. ß-D-Glucan has been detected in IFI caused by Aspergillus, Candida and Fusarium spp. The Fungitell Assay (Associates of Cape Code, Inc.) was developed and validated for detection of ß-D-Glucan in peripheral blood. Up to date information about clinical performance of the Fungitell Assays in bronchoalveolar lavage fluid (BAL) is limited. This study will therefore evaluate clinical and diagnostic performance of the Fungitell Assay in BAL from patients with solid organ transplant or hematologic malignancy. In addition Mn/A-Mn, the lateral flow device test for aspergillosis, and Galactomannan, as well as PCR will be determined and used as comparators for BDG performance.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04932967 -
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
|
||
Not yet recruiting |
NCT02900768 -
Effects of Exercise on Allogeneic Stem Cell Transplant
|
N/A | |
Recruiting |
NCT04082910 -
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT05510089 -
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
|
N/A | |
Terminated |
NCT04093622 -
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
|
||
Recruiting |
NCT06106360 -
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
|
||
Recruiting |
NCT06225856 -
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT02828462 -
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
|
||
Completed |
NCT01714180 -
Effect of Body Mass on Acyclovir Pharmacokinetics
|
N/A | |
Completed |
NCT03241550 -
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
|
Phase 1 | |
Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
Completed |
NCT02598752 -
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
|
||
Completed |
NCT02880709 -
The Effect of Special Diets in Hematological Cancer Patients
|
Phase 4 | |
Completed |
NCT00894049 -
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
|
Phase 2 | |
Completed |
NCT04687982 -
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
|
N/A | |
Completed |
NCT00897260 -
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
|
N/A | |
Recruiting |
NCT03850366 -
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
|
Phase 2 | |
Not yet recruiting |
NCT06066255 -
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
|
Phase 2 | |
Enrolling by invitation |
NCT05364359 -
Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy
|
N/A | |
Recruiting |
NCT04841447 -
Membrane Target Detection for Leukemia Treatment
|